Targeting key players of neuroendocrine differentiation in prostate cancer
| dc.contributor.author | Zamora Álvarez, Irene | |
| dc.contributor.author | Freeman, Michael R. | |
| dc.contributor.author | Encío Martínez, Ignacio | |
| dc.contributor.author | Rotinen Díaz, Mirja Sofia | |
| dc.contributor.department | Ciencias de la Salud | es_ES |
| dc.contributor.department | Osasun Zientziak | eu |
| dc.date.accessioned | 2024-05-09T17:34:45Z | |
| dc.date.available | 2024-05-09T17:34:45Z | |
| dc.date.issued | 2023 | |
| dc.date.updated | 2024-05-09T17:25:55Z | |
| dc.description.abstract | Neuroendocrine prostate cancer (NEPC) is a highly aggressive subtype of prostate cancer (PC) that commonly emerges through a transdifferentiation process from prostate adenocarcinoma and evades conventional therapies. Extensive molecular research has revealed factors that drive lineage plasticity, uncovering novel therapeutic targets to be explored. A diverse array of targeting agents is currently under evaluation in pre-clinical and clinical studies with promising results in suppressing or reversing the neuroendocrine phenotype and inhibiting tumor growth and metastasis. This new knowledge has the potential to contribute to the development of novel therapeutic approaches that may enhance the clinical management and prognosis of this lethal disease. In the present review, we discuss molecular players involved in the neuroendocrine phenotype, and we explore therapeutic strategies that are currently under investigation for NEPC. | en |
| dc.description.sponsorship | This research was funded by: The Spanish Ministry of Science, Innovation and Universities, grant number: PID2019-109577RA-I00/AEI/10.13039/501100011033; The Spanish Ministry of Science, Innovation and Universities (Ramón y Cajal Program), grant number: RYC-2018-023874-I (M.R.); The Department of Health, Government of Navarre, grant number: 026/2022. | en |
| dc.format.mimetype | application/pdf | en |
| dc.identifier.citation | Zamora, I., Freeman, M. R., Encío, I. J., Rotinen, M. (2023) Targeting key players of neuroendocrine differentiation in prostate cancer. International Journal of Molecular Sciences, 24(18), 1-22. https://doi.org/10.3390/ijms241813673. | en |
| dc.identifier.doi | 10.3390/ijms241813673 | |
| dc.identifier.issn | 1661-6596 | |
| dc.identifier.uri | https://academica-e.unavarra.es/handle/2454/48089 | |
| dc.language.iso | eng | en |
| dc.publisher | MDPI | en |
| dc.relation.ispartof | International Journal of Molecular Sciences 2023, 24(18), 13673 | en |
| dc.relation.projectID | info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/PID2019-109577RA-I00/ES/ | |
| dc.relation.projectID | info:eu-repo/grantAgreement/Gobierno de Navarra//026%2F2022/ | |
| dc.relation.publisherversion | https://doi.org/10.3390/ijms241813673 | |
| dc.rights | © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. | en |
| dc.rights.accessRights | info:eu-repo/semantics/openAccess | |
| dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
| dc.subject | Lineage plasticity | en |
| dc.subject | Neuroendocrine transdifferentiation | en |
| dc.subject | Prostate cancer | en |
| dc.subject | Targeted therapy | en |
| dc.title | Targeting key players of neuroendocrine differentiation in prostate cancer | en |
| dc.type | info:eu-repo/semantics/article | |
| dc.type.version | info:eu-repo/semantics/publishedVersion | |
| dspace.entity.type | Publication | |
| relation.isAuthorOfPublication | 599ca381-1fd2-4a23-93ab-4373837eb6e0 | |
| relation.isAuthorOfPublication | ecbb6fbe-3bda-4cad-945f-f263c1af5981 | |
| relation.isAuthorOfPublication.latestForDiscovery | 599ca381-1fd2-4a23-93ab-4373837eb6e0 |